QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.103.056002v1 307/2/682    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lindner, M. D. Articles by Gribkoff, V. K. Search for Related Content PubMed PubMed Citation Articles by Lindner, M. D. Articles by Gribkoff, V. K.

BEHAVIORAL PHARMACOLOGY

An Assessment of the Effects of Serotonin 6 (5-HT6) Receptor Antagonists in Rodent Models of Learning

Bristol-Myers Squibb Pharmaceutical Research Institute, Neuroscience Biology, Wallingford, Connecticut

Antagonists of serotonin 6 (5-HT6) receptors have been reported to enhance cognition in animal models of learning, although this finding has not been universal. We have assessed the therapeutic potential of the specific 5-HT6 receptor antagonists 4-amino-N-(2,6-bis-methylamino-pyrimidin-4-yl)-benzenesulfonamide (Ro 04-6790) and 5-chloro-N-(4-methoxy-3-piperazin-1-yl-phenyl)-3-methyl-2-benzothiophenesulfonamide (SB-271046) in rodent models of cognitive function. Although mice express the 5-HT6 receptor and the function of this receptor has been investigated in mice, all reports of activity with 5-HT6 receptor antagonists have used rat models. In the present study, receptor binding revealed that the pharmacological properties of the mouse receptor are different from the rat and human receptor: Ro 04-6790 does not bind to the mouse 5-HT6 receptor, so all in vivo testing included in the present report was conducted in rats. We replicated previous reports that 5-HT6 receptor antagonists produce a stretching syndrome previously shown to be mediated through cholinergic mechanisms, but Ro 04-6790 and SB-271046 failed to attenuate scopolamine-induced deficits in a test of contextual fear conditioning. We also failed to replicate the significant effects reported previously in both an autoshaping task and in a version of the Morris water maze. The results of our experiments are not consistent with previous reports that suggested that 5-HT6 antagonists might have therapeutic potential for cognitive disorders.

Address correspondence to: Dr. Mark D. Lindner, Bristol-Myers Squibb Pharmaceutical Research Institute, Department of Neuroscience, 5 Research Parkway, Wallingford, CT 06492. E-mail: mark.lindner{at}bms.com

This article has been cited by other articles:

				P. Svenningsson, E. T. Tzavara, H. Qi, R. Carruthers, J. M. Witkin, G. G. Nomikos, and P. Greengard Biochemical and Behavioral Evidence for Antidepressant-Like Effects of 5-HT6 Receptor Stimulation J. Neurosci., April 11, 2007; 27(15): 4201 - 4209. [Abstract] [Full Text] [PDF]

				R. Lydic, R. Garza-Grande, R. Struthers, and H. A. Baghdoyan Nitric oxide in B6 mouse and nitric oxide-sensitive soluble guanylate cyclase in cat modulate acetylcholine release in pontine reticular formation J Appl Physiol, May 1, 2006; 100(5): 1666 - 1673. [Abstract] [Full Text] [PDF]

				J. C. Talpos, L. S. Wilkinson, and T. W. Robbins A comparison of multiple 5-HT receptors in two tasks measuring impulsivity J Psychopharmacol, January 1, 2006; 20(1): 47 - 58. [Abstract] [PDF]